Figure 4.

The effect of WIN 55-212.2 mesylate on CAFs phenotype is mainly mediated by CB₂. (a) Representative immunoblot of α-SMA expression in CAFs isolated from two different explants (CAF1/CAF2) treated with WIN 55-212.2 mesylate 2.5 µM for 24 h in presence or not of AM281 and JTE-907 0.5 µM. Cells were pre-treated for 3 h with the antagonists, then WIN 55-212.2 mesylate was added. (b) Quantitative results of western blot analysis. Relative expressions were normalized with respect to GAPDH and shown as FC respect to control cells maintained in serum-deprived medium (Untr). Data represent means ± SEMs of three independent biological replicates performed on two different patient-derived CAFs. One-way ANOVA, Bonferroni’ corrected. * p < 0.05 versus Untr; § p < 0.05 versus WIN. (c) Gelatin zymography of conditioned media (10 fold concentrated) from CAFs treated as above. The white numbers in bolt indicate quantification of two independent biological replicates.